Clinical trials: Intestinal Mucositis, open to volunteers
Colo-rectal Cancer
Effect of Synbiotic Supplementation on the Prevention of Mucositis in Cancer Patients Undergoing Chemotherapy
Introduction: In the 2023-2025 period, colorectal cancer (CRC) will be the third most common type of cancer in Brazil. The most commonly used therapeutic approaches are chemotherapy (QTx) and radiotherapy (RTx).
- Trial name
- NCT06576986
- Testing
- Symbiotic, Maltodextrin
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Federal University of Minas Gerais
Intestinal Mucositis, Inflammation
Semaglutide in Auto-HSCT
The primary objective of this clinical trial is to ievaluate the effect of semaglutide (GLP-1 receptor agonist) in reducing intensity of gastrointestinal (GI) mucositis in patients undergoing high-dosage chemotherapy followed by…
- Conditions
- Intestinal Mucositis, Inflammation, Chemotherapeutic Toxicity
- Trial name
- PROTECT (NCT06449625)
- Testing
- Semaglutide Pen Injector [Ozempic]
- Volunteers
- 40 people
- Sponsor
- Klaus Gottlob Müller
Pelvic Toxicity, Radiation Toxicity
Gut Microbiome in Gynecological Cancer Patients With Pelvic Toxicity: Controls Versus Ozone Treatment. (MicrOzoGineTox)
Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments.
- Conditions
- Pelvic Toxicity, Radiation Toxicity, Chemotherapy Toxicity, Gynecological Tumors
- Trial name
- MicrOGineTox (NCT07259681)
- Where
- 2 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Bernardino Clavo, MD, PhD
Colorectal Cancer
Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis
Colorectal cancer (CRC) represents one of the most common cancers worldwide and 5-Fluorouracil (5-FU) is still the mainstay of treatment.
- Trial name
- NCT07736495
- Testing
- alpha lipoic acid 600 mg twice daily
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University